In the global medical devices industry, there were 32 private equity deals announced in Q3 2024, worth a total value of $10.9bn, according to GlobalData’s Deals Database. The $8.9bn institutional buy-out (ibo) R1 RCM Holdco by Dubilier & Rice, Clayton and TowerBrook Capital Partners was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Medical Devices Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity increased by 252% in Q3 2024 compared with the previous quarter’s total of $3.1bn and rose by 19% as compared to Q3 2023. Related deal volume increased by 7% in Q3 2024 versus the previous quarter and was 23% higher than in Q3 2023.
Notably, foreign direct investments (fdi)-related deals accounted for a 47% share of the global medical devices industry’s private equity deal activity in Q3 2024, up 50% over the previous quarter.
The top-ranked financial advisors supporting these private equity deals in 9M 2024 were Jefferies Financial Group; Goldman Sachs Group; Harris Williams with 4, 3, 3 deals respectively.
The top-ranked legal advisors supporting these private equity deals in 9M 2024 were Kirkland & Ellis; Morgan, Lewis & Bockius; Ropes & Gray with 11, 3, 3 deals respectively.
For further understanding of GlobalData's Medical Devices Industry Mergers And Acquisitions Deals By Top Themes In Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.